StreetAlpha.app
Home › Stocks › SVRA

Savara Inc (SVRA)

Healthcare
$4.48
▲ +0.34%
LAST CLOSE · NOV 17

Savara is a biopharmaceutical company developing MOLBREEVI, an inhaled investigational drug for a rare lung disease. It last closed at $4.48 on Nov 17, up 0.34% on the day. The average 12-month price target from 2 analysts is $11.00 (+145.5% from the last close), with a high of $12.00 and a low of $10.00.

AI Auto Pilots
Is SVRA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$152.7M
EPS (diluted)
−$0.60
Free cash flow
−$130.9M
Valuation
Market cap
$988.4M
220.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.8M
At Sep 30
Debt
$30.2M
At Sep 30
Shareholder equity
$107.8M
Shares outstanding
220.6M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$43.0M−$43.0MFY2021FY2022: −$38.1M−$38.1MFY2022FY2023: −$54.7M−$54.7MFY2023FY2024: −$95.9M−$95.9MFY2024FY2025: −$118.8M−$118.8MFY2025

From SVRA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated SVRA in the past 90 days, not enough for a consensus
Average 12-month target
$11.00
▲ 145.5% upside

Based on 2 analysts who set a price target on SVRA in the past 90 days. The average target is $11.00, with a high of $12.00 and a low of $10.00, compared with the last close of $4.48.

Low $10.00Avg $11.00High $12.00
Blue marker: last close $4.48
Highest target$12.00
Average target$11.00
Lowest target$10.00
Latest rating changes
HC Wainwright & Co.Assumed coverage
Nov 12Buy$10
JP MorganInitiated
Oct 7Buy$12
DateFirmActionRatingPrice target
Nov 12HC Wainwright & Co.Assumed coverageBuy$10
Oct 7JP MorganInitiatedBuy$12
Loading…

Technical Analysis

SVRA · as of the Nov 17 close · updated after every close
Downtrend

The stock is 5% below its 20 day and 9% below its 50 day average. It is 19% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 43). The nearest support is the swing low (Oct 16) at $4.44, and the nearest resistance the Pivot R1 at $4.60.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 6.7%/day
Key levels
$7.0152 week high+56.5%
$5.32200 day average+18.8%
$5.27100 day average+17.6%
$4.99Swing high (Oct 20)+11.4%
$4.9050 day average+9.4%
$4.7120 day average+5.1%
$4.60Pivot R1+2.7%
$4.48Pivot+0.0%
$4.48Last close
$4.44Swing low (Oct 16)−0.9%
$4.35Pivot S1−2.9%
$4.1352 week low−7.8%
Indicators
RSI (14)42.80Middle of its rangeNeutral
MACD-0.07Below its signal lineBearish
Stochastic23.1Middle of its rangeNeutral
ADX (14)15.0No clear trend
Williams %R-82.4Oversold below −80, overbought above −20Oversold
CCI (20)-98.6Oversold below −100, overbought above 100Neutral
Rate of change−5.7%Change over 10 sessionsBearish
ATR (14)$0.30Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SVRA

What happened before

See how SVRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SVRA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SVRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SVRA in the last 90 days.

Loading…

See today’s whale options flow across the market →

SVRA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲101 buying vs 71 selling
  • ●Held by funds -0.0 pts
  • ●Funds holding +1
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding183182+0.5%
In funds' top 10660.0%
Held by funds101.5%101.6%−0.0 pts
New / increased26 / 7522 / 70+9.8%
Reduced / sold out46 / 2557 / 26−14.5%
Put/call ratio0.12––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SVRA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SVRA is in one of them and how their past SVRA trades turned out.

SVRA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SVRA in an article yet. Here's the latest on the wider market.

About Savara

Savara is a biopharmaceutical company that develops treatments for rare respiratory diseases. Its main product candidate, MOLBREEVI, is an investigational inhaled drug for patients with autoimmune pulmonary alveolar proteinosis, a rare lung disease in which a substance called surfactant builds up in the air sacs of the lungs. The drug is given through a nebulizer device and is not yet approved for sale. The company is based in Austin, Texas.

Headquarters
Austin, TX